Skip to main content
. Author manuscript; available in PMC: 2014 Jul 25.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 Apr 4;20(7):979–985. doi: 10.1016/j.bbmt.2014.03.016

Table 1.

Patient Characteristics

Unrelated
Transplantations
Matched Related
Transplantations
P Value
No. of patients 203 211
Patient age, median (range) 44.5 (18–69) 48 (23–71) .0233
Disease .2132
  AML 80 (39%) 75 (36%)
  MDS 21 (10%) 26 (12%)
  ALL 30 (15%) 19 (9%)
  NHL 32 (16%) 46 (22%)
  Other* 40 (20%) 45 (21%)
Conditioning .4541
  Bu/flu 70 (34%) 61 (29%)
  Bu/flu/TBI+ 38+(2) (20%) 43+(1) (21%)
  Flu/mel/TBI+ 11+(3) (7%) 13+(5) (9%)
  R+/− BEAM 19 (9%) 30 (14%)
  Other 60 (30%) 58 (27%)
Donor/recipient sex .0016
  F/f 33 (16%) 48 (23%)
  F/m 35 (17%) 55 (26%)
  M/f 58 (29%) 42 (20%)
  M/m 77 (38%) 66 (31%)
Donor/recipient CMV status .1952
  Neg/neg 62 (31%) 69 (33%)
  Neg/pos 65 (32%) 48 (23%)
  Pos/neg 22 (11%) 28 (13%)
  Pos/pos 54 (27%) 66 (31%)
Donor age, median (range) 36.5 (18–60) 46.5 (18–75) <.0001
CD 34+median (range), 106/kg 7.28 (1.49–19.12) 5.78 (2.12–14.05) <.0001
HLA match <.0001
  8/8 136 (67%) 194 (92%)
  7/8 67 (33%) 17 (8%)
Disease risk .3217
  Low 75 (37%) 88 (42%)
  High 128 (63%) 123 (58%)
Stem cell source .4960
  PBSC 198 (98%) 208 (99%)
  BM 5 (2%) 3 (1%)
No. of prior transplantations .0521
  0 193 (95%) 190 (90%)
  1 or more (auto) 10 (5%) 21 (10%)

AML indicates acute myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; M, male; F, female; Bu, busulfan; mel, melphalan; BEAM, carmustine, etoposide, cytarabine and melphalan; TBI, total body irradiation; PBSC, peripheral blood stem cells; BM, bone marrow.

*

Other includes chronic myelogenous leukemia, MPD, multiple myeloma, chronic lymphatic leukemia, PLL, and Hodgkin disease.

Other includes VP16/TBI, CY/TBI, BAC, CY/FLU/TBI, CVB+(R), and BU/CY.

Fisher exact test. The others were chi-square test for the categorical variables.